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CORRESPONDENCE 
To the Editor
We read the interesting article “Acute Effects of Intravenous Ad-
ministration of Pamidronate in Patients with Osteoporosis” in 
the Journal of Korean Medical Science by Lim et al. (1). We would 
like to comment and compare these data to a study recently pub-
lished by our research group (2). The two studies had different 
initial aims, but still they share the same results in determining 
the modulatory effect of inflammation of aminobisphospho-
nates, such as  pamidronate. The pamidronate belongs to the 
family of aminobisphosphonates (N-BPs), currently the major 
class of drugs used for the treatment of osteoporosis and other 
diseases characterized by increased bone resorption. The im-
mune modulation exerted by pamidronate has not yet fully been 
understood (3). In vitro experiments have shown an anti-inflam-
matory effect of this N-BP; (4, 5) as well as a pro-inflammatory 
one (6, 7). Moreover contrasting results were obtained when 
pamidronate was used for the treatment of different inflamma-
tory or immunologic diseases, such as rheumatoid arthritis (8, 
9) or systemic sclerosis. 
  The aminobiphosphonates act on farnesylpyrophosphate syn-
thase (FPPS) and inhibit the mevalonate pathway, the latter be-
ing responsible for production of cholesterol and isoprenoid lip-
ids. In particular we can hypothesize that the inflammatory phe-
notype is due to lack of enzymes downstream the FPPS, and in 
particular the lack of geranylgeranyl-pyrophosphate (GGPP) 
could be associated to the activation of caspase-1 and the high 
IL-1β release.
  Lim et al. (1) emphasized that in vivo infusion of pamidronate 
at a therapeutic dose of 30 mg  increased production of two in-
flammatory cytokines, IL-6 and TNF-α in serum. The increase 
is an acute effect after intravenous injection (1).
  Recently, our group demonstrated that pamidronate is able to 
increase the sensitivity to bacterial compounds both in the mu-
rine macrophagic cell line (Raw 264.7) and in Balb/c mice, by 
an incremental release of IL1β. These findings are in agreement 
with published data concerning inflammatory modulation in 
alendronate treated-mice (2). Moreover the effect of pamidro-
nate does not depend on its concentration, whereas it may be 
involved in the increase of susceptibility to pro-inflammatory 
compounds such as muramildipeptide or lipopolysaccaride (2). 
  In summary, we agree with the study by Lim et al. (1) and we 
emphasize the pivotal role of pamidronate in the modulation of 
inflammatory response.
Sincerely.
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